AMVUTTRA Tops $1B Quarter, But Alnylam Cuts Guidance as Second-Line Demand Normalizes

First-line shift and competitor setbacks bolster long-term TTR leadership case

ALNY · Earnings Call · 2026-07-30

A Blockbuster Quarter, Bracketed by a Guide Cut

Alnylam’s Q2 2026 report was a study in contrast — record revenue on one hand, a lowered outlook on the other. For the first time, AMVUTTRA crossed $1 billion in a single quarter in ATTR cardiomyopathy, a figure that implies an annual run rate of over $4 billion just 15 months into launch. CEO Yvonne Greenstreet opened the call with that milestone, calling it “a testament to both the commercial opportunity and Alnylam's execution.” — Yvonne Greenstreet, Chief Executive Officer · 2026-07-30 Yet the same presentation delivered a $200 million reduction to full-year TTR revenue guidance, a move that sent shares down sharply in the aftermarket. The tape tells a similar story: ALNY is down 26.7% over the last 90 days and 51.9% from its October 2025 peak. The market has been pricing in expectations that the launch’s early explosive growth may be partially a one-time bolus. Management now owns that miscalculation. CFO Jeff Poulton said plainly: “Guiding the market's expectations appropriately is important, and we didn't get it right with our original guidance. We own that.” — Jeffrey Poulton, Chief Financial Officer · 2026-07-30

Why the Cut? The Second-Line Pivot

The core driver is the normalization of second-line demand. Early in the launch, many patients who had been progressing on stabilizers — and had been waiting for an orthogonal mechanism — rapidly transitioned to AMVUTTRA. That pent-up wave has now subsided to a sustainable run-rate. Tolga Tanguler, Chief Commercial Officer, framed it as a natural evolution: “While those transitions continue, we are now seeing that portion of demand volume growth normalize toward a more sustainable underlying rate.” — Tolga Tanguler, Chief Commercial Officer · 2026-07-30 Notably, this is not a share loss. The company emphasizes that category growth is accelerating and that first-line starts now represent ~80% of new treatment initiations. The strategy has been to position AMVUTTRA as a foundational therapy — “first line” — and the data suggests they are taking share from tafamidis early. Tanguler noted that among prescribers who use AMVUTTRA, it now represents over 50% of new starts. The company is also rapidly expanding the prescriber base, adding over 1,700 new prescribers since launch. What does steady-state look like? When an analyst asked whether the 80/20 split is now the baseline, Tanguler clarified: “It’s mainly driven by the overall category... the overall volume shift into a lesser contribution of the new brands from switches for the entire category.” — Eliana Merle, Analyst · 2026-07-30 In other words, the mix shift is a market-wide phenomenon, not an Alnylam-specific problem. The market’s worry is whether first-line growth can accelerate fast enough to offset the second-line fade. Management remains confident, citing the huge untreated patient pool (80% still untreated), and renewed investments in diagnosis and community education. The 25% CAGR guidance for 2030 was reaffirmed, anchored on the durability of the TTR franchise.

Competitive Tailwinds: Competitor Failure and Delayed Generics

While the guide cut was a negative, two external developments have materially improved Alnylam’s competitive position. First, the CARDIO-TTRansform trial (AstraZeneca/Ionis’ eplontersen) failed its primary endpoint in ATTR-CM. Second, Pfizer’s tafamidis (Vyndaqel) loss of exclusivity in the U.S. has been pushed to 2031, giving Alnylam several more years before generic stabilizers enter. Yvonne Greenstreet was unequivocal about the competitive read-through: “there's likely to be one less branded competitor on the market... we're actually sort of more confident about our future outlook given these developments.” — Yvonne Greenstreet, Chief Executive Officer · 2026-07-30 This is a significant shift from the prior quarter, where the company was still hedging on the possibility that eplontersen could succeed. Pushkal Garg, R&D Chief, spent considerable time explaining why the eplontersen failure does not undermine confidence in TRITON-CM, the Phase III trial for nucresiran. He argued that the failure likely reflects molecule-specific issues (depth/speed of knockdown) and study design differences, not a class effect. He cited data showing that vutrisiran achieves deep TTR knockdown in a higher fraction of patients than eplontersen, and that nucresiran is expected to be even better: “over 99% of patients choosing nucresiran are expected to surpass this deep knockdown threshold.” — Pushkal Garg, Chief Research and Development Officer · 2026-07-30

We don't believe that the top line results shared a few weeks ago negate the hypothesis and rationale of using a silencer for ATTR-CM patients who are already on a stabilizer.
Pushkal Garg, Chief Research and Development Officer · 2026-07-30

This confidence is crucial because TRITON-CM is the next major catalyst for the franchise. The company has already expanded the trial to 1,750 patients, and management hints they may further adapt the protocol based on the full CARDIO-TTRansform dataset. The stock’s drawdown reflects skepticism, but the clinical team’s track record — HELIOS-B was a landmark success — gives them a credible basis for optimism.

Strategic Moves and Pipeline Depth

Beyond the TTR franchise, Alnylam is making notable moves to broaden its moat. Over the quarter, the company announced a series of AI collaborations spanning discovery, disease identification, and clinical practice — including a partnership with Inceptive for RNAi discovery and a large California health system for early ATTR-CM diagnosis. This is part of a broader strategy to scale impact. Also new is the collaboration with BeOne for AMVUTTRA commercialization in Mainland China and Macau. This opens a massive, underserved geography, though regulatory approval is still pending. The company also initiated Phase II trials for ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome–associated Alzheimer’s. On the financials, the company remains solidly profitable on a non-GAAP basis, with Q2 operating income of $318M. Total global net product revenues were ~$1.2B, up 74% YoY. The fundamentals confirm strong momentum: Total Revenue has grown from $774M in Q1 2025 to $1.17B in Q2 2026, a 50% sequential jump. But the company is also investing heavily in R&D — up 38% YoY — to support three Phase III trials.

The Bottom Line

Alnylam is navigating the classic challenge of a blockbuster drug launch: managing expectations after an extraordinary start. The guidance cut is a healthy corrective, and the underlying fundamentals — first-line share gains, fast-growing category, and a competitor setback — remain highly favorable. The stock has de-rated, but the long-term TTR leadership thesis is arguably stronger today than it was a year ago. For investors, the key debate is whether first-line adoption can keep pace. Management’s confidence is anchored in the 80% untreated pool and a prescriber expansion strategy that is still in early innings. One prior-quarter quote from Tolga captures the cyclical mindset: “Early second-line use is obviously driven by physicians treating patients progressing on stabilizers... as those patients have transitioned, second-line volume normalizes.” — Yvonne Greenstreet, Chief Executive Officer · 2026-04-30 That normalization is exactly what is playing out — and the company is now betting on the next wave. With a pipeline including nucresiran, zilebesiran, and early-stage CNS programs, Alnylam is not a one-trick pony. But the next 12 months will be decisive: execution on the first-line expansion and the TRITON-CM data will determine whether the 25% CAGR target is met. The company’s own probability of success messaging is confident, but the market will demand proof.